Cardiotoxicidad inducida por la quimioterapia desde las bases moleculares hasta la perspectiva clínica

Siegel, 2015, Cancer statistics, 2015: Cancer Statistics, 2015, CA Cancer J Clin., 65, 5, 10.3322/caac.21254 DeSantis, 2014, Cancer treatment and survivorship statistics, 2014: Cancer Treatment and Survivorship Statistics, 2014, CA Cancer J Clin., 64, 252, 10.3322/caac.21235 Yusuf, 2011, Radiation-induced heart disease: a clinical update, Cardiol Res Pract., 2011, 317659, 10.4061/2011/317659 Carver, 2007, American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects, J Clin Oncol Off J Am Soc Clin Oncol., 25, 3991, 10.1200/JCO.2007.10.9777 Florescu, 2013, Chemotherapy-induced Cardiotoxicity, Mædica, 8, 59 Seidman, 2002, Cardiac dysfunction in the trastuzumab clinical trials experience, J Clin Oncol Off J Am Soc Clin Oncol., 20, 1215, 10.1200/JCO.20.5.1215 Jiji, 2012, Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs, J Nucl Cardiol Off Publ Am Soc Nucl Cardiol., 19, 377, 10.1007/s12350-012-9512-2 Albini, 2010, Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention, J Natl Cancer Inst., 102, 14, 10.1093/jnci/djp440 Dolci, 2008, Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use, Am J Clin Pathol., 130, 688, 10.1309/AJCPB66LRIIVMQDR Frishman, 1997, Cardiovascular toxicity with cancer chemotherapy, Curr Probl Cancer., 21, 301, 10.1016/S0147-0272(97)80001-3 Pai, 2000, Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention, Drug Saf., 22, 263, 10.2165/00002018-200022040-00002 Rang HP. Rang et Dale's pharmacology. Edinburgh [u.a.]: Elsevier, Churchill Livingstone; 2016. Figueredo, 2011, The Negative Effects of Medications and Nonprescribed Drugs on the Heart, Am J Med., 124, 480, 10.1016/j.amjmed.2010.11.031 Zylberman, 2013, Consenso de diagnóstico, prevención y tratamiento de la cardiotoxicidad por tratamiento médico del cáncer, Rev Argent Cardiol., 81, 1 Brana, 2010, Cardiotoxicity, Ann Oncol., 21, vii173, 10.1093/annonc/mdq295 Lefrak, 1973, A clinicopathologic analysis of adriamycin cardiotoxicity, Cancer., 32, 302, 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2 Ewer, 1984, A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin, J Clin Oncol Off J Am Soc Clin Oncol., 2, 112, 10.1200/JCO.1984.2.2.112 2013, 1454 Khakoo, 2011, Cardiotoxicity due to cancer therapy, Tex Heart Inst J Tex Heart Inst St Lukes Episcop Hosp Tex Child Hosp., 38, 253 Schlitt, 2014, Cardiotoxicity and oncological treatments, Dtsch Ärztebl Int., 111, 161 Hurtado, 2011, Cardiotoxicidad por quimioterapia Un enfoque práctico para el clínico, Insufic Card., 6, 131 Adão, 2013, Cardiotoxicidade associada à terapêutica oncológica: mecanismos fisiopatológicos e estratégias de prevenção, Rev Port Cardiol., 32, 395, 10.1016/j.repc.2012.11.002 Slørdal, 2006, Heart failure induced by non-cardiac drugs, Drug Saf., 29, 567, 10.2165/00002018-200629070-00003 Curigliano, 2012, Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines, Ann Oncol., 23, vii155, 10.1093/annonc/mds293 Ozcelik, 2002, Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy, Proc Natl Acad Sci., 99, 8880, 10.1073/pnas.122249299 Serrano, 2012, Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors, Ann Oncol Off J Eur Soc Med Oncol ESMO., 23, 897, 10.1093/annonc/mdr348 Di Cosimo, 2011, Heart to heart with trastuzumab: a review on cardiac toxicity, Target Oncol., 6, 189, 10.1007/s11523-011-0203-8 Chavez-MacGregor, 2013, Trastuzumab-Related Cardiotoxicity Among Older Patients With Breast Cancer, J Clin Oncol., 31, 4222, 10.1200/JCO.2013.48.7884 Orphanos, 2009, Cardiotoxicity induced by tyrosine kinase inhibitors, Acta Oncol., 48, 964, 10.1080/02841860903229124 Liu, 2015, Protein kinase R-like ER kinase and its role in endoplasmic reticulum stress-decided cell fate, Cell Death Dis., 6, e1822, 10.1038/cddis.2015.183 Bovelli, 2010, Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines, Ann Oncol., 21, v277, 10.1093/annonc/mdq200 Plana, 2014, Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, J Am Soc Echocardiogr., 27, 911, 10.1016/j.echo.2014.07.012 Dogru, 2013, Evaluation of Cardiotoxicity via Speckle-Tracking Echocardiography in Patients Treated with Anthracyclines, Oncol Res Treat., 36, 10.1159/000356850 Reagan, 2013, Comparison of Cardiac Troponin I and T, Including the Evaluation of an Ultrasensitive Assay, as Indicators of Doxorubicin-induced Cardiotoxicity, Toxicol Pathol., 41, 1146, 10.1177/0192623313482056 Lotrionte, 2013, Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity, Am J Cardiol., 112, 1980, 10.1016/j.amjcard.2013.08.026 Smith, 2010, Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials, BMC Cancer., 10, 337, 10.1186/1471-2407-10-337 Rahman, 2007, Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation, Int J Nanomedicine., 2, 567 Bosch, 2013, Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies, J Am Coll Cardiol., 61, 2355, 10.1016/j.jacc.2013.02.072 Smiseth, 2013, Cardioprotection During Chemotherapy, J Am Coll Cardiol., 61, 2363, 10.1016/j.jacc.2013.02.073